How to Buy Connect Biopharma Holdings Stock
Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators.
Connect Biopharma Holdings stock last closed at $2.02, down 3.35% from the previous day, and has increased 0% in one year. It has overperformed other stocks in the Biotechnology industry by 0.13 percentage points. Connect Biopharma Holdings stock is currently +64.23% from its 52-week low of $1.23, and -47.12% from its 52-week high of $3.82.
At the moment, there are 62.96M CNTB shares outstanding. The market capitalization of CNTB is $127.19M. In the last 24 hours, 295,000 CNTB shares were traded.
How to Buy Connect Biopharma Holdings Stock
Not sure how to invest in Connect Biopharma Holdings stock? Here's how.
- Figure out where to buy Connect Biopharma Holdings stock: You need to decide on a stock brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you choose where to buy Connect Biopharma Holdings stock.
- Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Choose your payment method and add your details.
- Research Connect Biopharma Holdings stock: The Connect Biopharma Holdings ticker symbol is CNTB. Is Connect Biopharma Holdings stock a good investment? Should you buy shares of CNTB? How do CNTB's underlying business fundamentals look? Do top analysts think Connect Biopharma Holdings is a good buy? Why has CNTB's stock price moved recently? (Hint: Our stock research tools can help you figure out if CNTB is a good stock to buy).
- Place your CNTB purchase: Decide if you will purchase CNTB shares at the current market price or use a limit order to purchase CNTB shares at a given price.
- Monitor your CNTB position: Create a watchlist to keep tabs on your new investment in Connect Biopharma Holdings stock.
Step 1: Figure out where to buy Connect Biopharma Holdings stock
You need a brokerage account to access the NASDAQ market and buy CNTB stock.
Our favorite brokerage: eToro
We believe that eToro is the best brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to world markets: From Tech to Healthcare, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro offers a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal information so you are able to invest in CNTB today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to open a new trading account.
- Submit your data by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have opened your account on stock market apps, you can securely and quickly fund your account:
Watch the walkthrough below if you need help depositing funds into your new brokerage account.
Step 4: Research Connect Biopharma Holdings stock
After you have figured out the best place to buy Connect Biopharma Holdings stock, it's critical to analyze their stock before you buy, so you truly comprehend the risk as well as the upside.
Connect Biopharma Holdings shares at a glance
CNTB Due Diligence Checks
WallStreetZen was built to help part-time investors perform more accurate fundamental analysis.
You can see all of the due diligence checks on CNTB's stock page.
Is CNTB stock overvalued?
Investors use many financial metrics, analyses, models, and charts to gauge CNTB's true value.
Using relative valuations metrics:
- CNTB could be undervalued based on its P/B ratio of 2.98x, relative to Biotechnology industry P/B ratio of 5.23x
You can do more valuation research on CNTB's stock here.
CNTB Financial Summary
Signs that CNTB is financially healthy:
- There are more short-term assets than long-term liabilities on the CNTB balance sheet.
- There are more short-term assets than short-term liabilities on the CNTB balance sheet.
Signs that CNTB is not financially healthy:
- CNTB profit margin has gone down from -66.1% to -27,727.9% in the past year.
- CNTB has a relatively high debt to equity ratio of 0.41.
- CNTB has $46.03M in cash and short term investments. This is not sufficient to cover its annual cash burn of $57.61M.
- CNTB has cash burn of 57605000. It does not have sufficient cash and short-term investments to cover this.
Do analysts think it's a good time to buy Connect Biopharma Holdings stock
Out of 6 Equities analysts who track CNTB, the consensus analyst rating on Connect Biopharma Holdings is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Latest CNTB Analyst Forecasts
Julian Harrison, a top 2% analyst from BTIG reiterates CNTB with a strong buy rating and maintains their CNTB price target from $10.00 to $10.00, on Apr 1, 2026.
You can dive deeper into what analysts are saying on the Connect Biopharma Holdings stock forecast page.
CNTB Momentum
CNTB Growth Numbers
Last year, CNTB revenue was $233.00k. Over the last one years, CNTB's revenue has increased by -99.1% per year. This was slower than the Biotechnology industry average of 34.2%.
You can research CNTB's earnings and revenue performance here.
Latest Insiders Trades at CNTB
Over the past year, insiders at CNTB have bought more shares than they have sold.
James Huang, Director of CNTB, was the latest CNTB insider to buy. They bought $371,550.00 worth of CNTB shares on May 29, 2026.
Dig into more about who owns CNTB shares here.
Does CNTB provide a stable income stream?
No, Connect Biopharma Holdings doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your CNTB purchase
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly the easiest way to buy. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at an exact dollar amount limit, place a limit order.
Click the Open Trade button and eToro will execute your order.
If you want additional info about buying stocks on eToro, watch the how to video below:
Step 6: Monitor your CNTB position
Now that you own some CNTB stock, you'll want to keep up with your shares.
Make a watchlist to track the latest developments regarding your CNTB stock.
CNTB Feed
How to Buy Stock in Connect Biopharma Holdings
To reiterate, here are the 6 steps for buying Connect Biopharma Holdings stock:
- Figure out where to buy Connect Biopharma Holdings stock
- Sign up for a brokerage account
- Fund your brokerage account
- Research Connect Biopharma Holdings stock
- Place your CNTB purchase
- Monitor your CNTB position
If you are looking for a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to get the latest scoop on your new investment in Connect Biopharma Holdings, get started below.
More Content You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.